Rung 4 · Strong
Immunotherapy around surgery for non-small cell lung cancer
Longer survival in one large randomized trial.
TreatmentWith your doctor
What studies found
In KEYNOTE-671, pembrolizumab added to chemotherapy before surgery and continued afterward gave 36-month survival of 71% versus 64% with chemotherapy alone, in 797 patients with operable cancer.
The catch
The survival benefit has been confirmed in one trial so far.
What to do
If your cancer can be operated on, ask whether immunotherapy before and after surgery fits your tumor.
Sources
Rung 4 of 5, Strong: At least one large randomized trial, or very large consistent studies, on this exact question. How we score
To take it to your doctor, print this page.
Step by step
For the whole picture, from prevention and screening to treatment and life after, see the lung cancer page.
Related
- Tumor gene testing before lung cancer treatmentRung 5 · EstablishedWith your doctorRung 5 · EstablishedTreatmentWith your doctor
- Amivantamab plus lazertinib for advanced EGFR lung cancerRung 4 · StrongWith your doctorRung 4 · StrongTreatmentWith your doctor
- Durvalumab after chemoradiation for limited-stage small cell lung cancerRung 4 · StrongWith your doctorRung 4 · StrongTreatmentWith your doctor
- Targeted pills after surgery or chemoradiation for EGFR or ALK lung cancerRung 4 · StrongWith your doctorRung 4 · StrongTreatmentWith your doctor
- Tarlatamab for small cell lung cancer that returns after chemotherapyRung 4 · StrongWith your doctorRung 4 · StrongTreatmentWith your doctor